Your veterinarian will discontinue the use of Adriamycin ® if heart disease is detected at any time. (caninecancer.com)
Less than 10 % of our patients develop heart disease as a result of Adriamycin ® chemotherapy. (caninecancer.com)
The approval was based on a clinical trial comparing brentuximab vedotin plus conmbination chemotherapy (Adriamycin [doxorubicin], vinblastine and dacarbazine, or AVD) vs a chemotherapy - only regimen commonly used to treat cHL (AVD plus bleomycin, also known as ABVD). (cancernetwork.com)